Amgen Declares Third Quarter Dividend for 2025
Amgen, a pioneering biotechnology company with over four decades of experience, continues to be a significant player in the industry. Known for its innovative medicines that help patients fight some of the world's toughest diseases, Amgen is also a top dividend-paying company.
The company recently declared a $2.38 per share dividend for the third quarter of 2025, to be paid on September 12, 2025. This dividend, part of Amgen's consistent dividend policy, translates to an annualized dividend of $9.52 per share and a yield around 3.2% to 3.34% as of mid-2025.
Amgen's dividend history is impressive, showing steady growth over 15 years. The company's dividend payout ratio ranges from 44% to 87%, reflecting solid coverage by earnings and robust distribution to shareholders. The most recent ex-dividend date was August 22, 2025, with stockholders of record as of this date eligible for the dividend.
Beyond its dividend offerings, Amgen is a key player in the Nasdaq-100 Index and was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024.
However, like any business, Amgen faces risks. Global economic conditions may magnify certain risks that affect its business. The effects of global climate change and related natural disasters could negatively impact its operations. The adoption of new tax legislation or exposure to additional tax liabilities could also impact its business.
Amgen's pipeline builds on its existing portfolio of medicines to treat various diseases, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. However, the protection offered by Amgen's patents and patent applications may be challenged, invalidated, or circumvented by competitors.
Amgen's business performance could affect or limit the ability to declare a dividend or pay a dividend. The company may face safety, side effects, or manufacturing problems with its products after they are on the market, which could impact its business. Additionally, Amgen relies on collaborations with third parties for the development of some product candidates and for the commercialization and sales of some commercial products.
Investors should also be aware of potential risks such as government investigations, litigation, and product liability claims. Amgen's stock price is volatile and may be affected by various events. The company may not be able to access the capital and credit markets on terms that are favorable to it, or at all.
Sales of Amgen's products may be affected by political and public scrutiny, reimbursement policies imposed by third-party payers, and domestic and international trends toward managed care and healthcare cost containment. Amgen's research, testing, pricing, marketing, and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.
A breakdown, cyberattack, or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity, and availability of its systems and data. Certain raw materials, medical devices, and component parts for Amgen's products are supplied by sole third-party suppliers, which could pose a risk if these suppliers face disruptions.
For more information about Amgen, visit Amgen.com or follow them on various social media platforms. Contact information for media and investors is also provided.
In summary, while Amgen offers an attractive dividend policy to income-focused investors, it is important to consider the various risks that could impact its business. As with any investment, thorough research and understanding of these risks are crucial.
- Despite its attractive dividend policy, Amgen's business performance, including potential risks from global economic conditions, regulatory challenges, and product liability claims, could impact its ability to pay future dividends.
- As investors consider Amgen for its finance opportunities, it's crucial to study its business, including its investing strategies in developing new medicines and its partnerships with third parties, as these factors may significantly affect its long-term growth and dividend prospects.
